Synergistic combination therapy with cotylenin A and vincristine in multiple myeloma models

INTERNATIONAL JOURNAL OF ONCOLOGY Volume 46 Page 1801-1809 published_at 2015
アクセス数 : 2360
ダウンロード数 : 80

今月のアクセス数 : 64
今月のダウンロード数 : 1
File
Title
Synergistic combination therapy with cotylenin A and vincristine in multiple myeloma models
Creator
Adachi Koji
OKADA MASAHIRO
KUMANOMIDOU SATOSHI
TANAKA JUNKO
Source Title
INTERNATIONAL JOURNAL OF ONCOLOGY
Volume 46
Start Page 1801
End Page 1809
Journal Identifire
ISSN 1019-6439
Descriptions
Multiple myeloma is a malignant proliferative disease of plasma cells in the bone marrow and remains largely incurable. Cotylenin A, a fusicoccane diterpene glycoside with a complex sugar moiety, was isolated as a plant-growth regulator. Cotylenin A has been shown to inhibit the growth of various cancer cells. Herein, we examined the anti-myeloma effects of cotylenin A using five human myeloma cell lines (RPMI-8226, KMS-11, KMS-26, KMS-12 PE and KMS-12 BM) and xenografts in immunodeficient mice. Cotylenin A and vincristine synergistically inhibited the growth and induced apoptosis in myeloma cells. While other microtubule-disturbing agents also showed co-operative effects with cotylenin A, other anticancer agents, such as doxorubicin, cisplatin, camptothecin, methotrexate, gemcitabine and 5-fluorouracil, did not show such co-operation with cotylenin A. These differences might be attributed to the effects on autophagic responses. Combined treatment with cotylenin A and vincristine induced autophagy (formation of LC3-II and degradation of p62 protein). However, doxorubicin did not enhance the autophagy induced by cotylenin A. A colony-forming assay indicated that the combined treatment with cotylenin A and vincristine more effectively suppressed the formation of large colonies, which have higher self-renewal activity than vincristine alone. Expression of pluripotency-associated transcription factor Sox2 mRNA in RPMI-8226 myeloma cells was significantly suppressed by treatment with cotylenin A. Combined treatment with cotylenin A and vincristine significantly inhibited the growth of KMS-26 myeloma cells as xenografts. Our results suggest that the combination of cotylenin A and vincristine may have therapeutic value. Recently, it was reported that cotylenin A modulates the 14-3-3 intracellular signaling pathway. The 14-3-3 proteins may be novel targets in treating myeloma. However, our study could not explain how the sensitization to vincristine is related to the effects of cotylenin A on the
Subjects
myeloma cell ( Other)
cotylenin A ( Other)
vincristine ( Other)
stemness ( Other)
xenograft ( Other)
Language
eng
Resource Type journal article
Publisher
Spandidos Publications
Date of Issued 2015
Publish Type Version of Record
Access Rights open access
Relation
[DOI] 10.3892/ijo.2015.2882